Patent · US Active

Agonistic CD40 antibodies

US11702478B2 · kind B2 · utility

0Cited by

3References

13Claims

0Family size

Assignee

MAB Discovery GmbH · DE

Inventors

Stephan Fischer · Weilheim, DE
Karsten BECKMANN · Albany, US

Key dates

Filing date	Sep 19, 2018
Grant date	Jul 18, 2023
Priority date	—
Expiry date	Mar 1, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fey mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.